Rovi/€ROVI
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Rovi
Laboratorios Farmaceuticos ROVI SA, ticker ROVI, is a Spain-based pharmaceutical company primarily engaged in developing, manufacturing, and commercializing pharmaceutical products. The company's activities span both domestic and international markets, focusing on a range of medical and drug treatments. Founded in 1946, ROVI continues to expand its reach and influence in the healthcare and pharmaceutical sectors.
Ticker
€ROVI
Sector
Primary listing
BME
Employees
2,188
Headquarters
Website
Rovi Metrics
BasicAdvanced
€2.8B
23.42
€2.37
-
€0.76
1.37%
Price and volume
Market cap
€2.8B
52-week high
€66.55
52-week low
€45.52
Average daily volume
13K
Dividend rate
€0.76
Financial strength
Current ratio
3.016
Quick ratio
1.298
Long term debt to equity
15.378
Total debt to equity
19.535
Dividend payout ratio (TTM)
39.48%
Interest coverage (TTM)
53.49%
Profitability
EBITDA (TTM)
173.122
Gross margin (TTM)
62.40%
Net profit margin (TTM)
16.73%
Operating margin (TTM)
20.79%
Effective tax rate (TTM)
23.12%
Revenue per employee (TTM)
€330,000
Management effectiveness
Return on assets (TTM)
10.46%
Return on equity (TTM)
20.34%
Valuation
Price to earnings (TTM)
23.423
Price to revenue (TTM)
3.918
Price to book
4.52
Price to tangible book (TTM)
4.79
Price to free cash flow (TTM)
26.357
Free cash flow yield (TTM)
3.79%
Free cash flow per share (TTM)
2.105
Dividend yield (TTM)
1.37%
Forward dividend yield
1.37%
Growth
Revenue change (TTM)
-9.39%
3-year revenue growth (CAGR)
-1.62%
10-year revenue growth (CAGR)
11.57%
10-year dividend per share growth (CAGR)
18.66%
What the Analysts think about Rovi
Analyst ratings (Buy, Hold, Sell) for Rovi stock.
Bulls say / Bears say
Sales of ROVI’s specialty pharmaceutical business climbed 13% to €237.4 million in the first half of 2025, offsetting CDMO headwinds (Rovi)
Okedi® (Risperidone ISM®) sales surged 115% year-over-year to €26.9 million in H1 2025, underscoring strong market uptake of ROVI’s proprietary products (Rovi)
ROVI secured €36.3 million in non-dilutive aid from the CDTI for its LAISOLID project, supporting R&D through August 2026 and bolstering its innovation pipeline (Rovi)
CDMO revenue plunged 35% year-over-year to €77.2 million in H1 2025, creating a significant drag on overall performance (Rovi)
Operating revenue fell 4% to €314.6 million in the first half of 2025 amid the CDMO downturn, missing the company’s prior-year levels (Rovi)
EBITDA declined 6% to €65.6 million and net profit dropped 10% to €39.7 million in H1 2025, reflecting margin pressure from higher R&D investment (Rovi)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2025.
Rovi Financial Performance
Revenues and expenses
Rovi Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rovi stock?
Rovi (ROVI) has a market cap of €2.8B as of November 09, 2025.
What is the P/E ratio for Rovi stock?
The price to earnings (P/E) ratio for Rovi (ROVI) stock is 23.42 as of November 09, 2025.
Does Rovi stock pay dividends?
Yes, the Rovi (ROVI) stock pays dividends to shareholders. As of November 09, 2025, the dividend rate is €0.75743 and the yield is 1.37%. Rovi has a payout ratio of 39.48% on a trailing twelve-month basis.
When is the next Rovi dividend payment date?
The next Rovi (ROVI) dividend payment date is unconfirmed.
What is the beta indicator for Rovi?
Rovi (ROVI) does not currently have a Beta indicator.